G J Rustin

Use of tumour markers in monitoring the course of ovarian cancer.

S M Bentzen, M. Piccart, G. Rustin, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer

T. Ganesan, G. Rustin, P. Nathan, 2010, British Journal of Cancer.

A Review of the Role of Established Tumour Markers

G. Rustin, G J Rustin, G. Beastall, 1991, Annals of clinical biochemistry.

A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).

A R Padhani, A. Padhani, G. Rustin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels.

G. Rustin, T. Meyer, M. Marples, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular and biological factors in the pathogenesis of ovarian cancer.

G. Rustin, J. Berek, C. Tropé, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.